Creative Medical Technology Holdings, Inc. CELZ 深 沪
已收盘 02-06 16:00:00 美东时间
1.93
+0.150
+8.43%
华盛通- 最 高1.9799
- 今 开1.86
- 成交量 3.75万股
- 最 低 1.80
- 昨 收 1.78
- 总市值 674.47万
- 52周最高 6.90
- 市盈率 静 --
- 换手率 1.07%
- 52周最低 1.504
- 委 比 -86.92%
- 总股本 349.47万
- 历史最高 51.45
- 量 比 1.42
- 振 幅 10.11%
- 历史最低 1.504
- 每 手 1
- 风险率 0.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 345.6% to $3.62 during...
01-20 20:05
Creative Medical Technology Holdings shares are trading higher after the company received regulatory clearance for its BioDefense burn pit program and said no additional fundraising is required to execute the initiative.
Creative Medical Technology Holdings shares are trading higher after the compan...
01-06 22:18
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced regulatory approval for its BioDefense Inc. Burn Pit Initiative, a program aimed at addressing long-term health consequences for U.S. military veterans exposed to toxic burn pits. The initiative leverages AI and induced pluripotent stem cell (iPSC) technology to build a comprehensive database and develop regenerative solutions. No additional fundraising is required, as the progra...
01-06 14:15
Creative Medical Technology Completes Patient Enrollment In FDA-Cleared ADAPT Clinical Trial For CELZ-201
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the successful completion of patient enrollment in its
2025-12-17 22:16
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
Creative Medical Technology Holdings, Inc. (CELZ) successfully completed patient enrollment in its FDA-cleared ADAPT clinical trial for CELZ-201, a cell therapy targeting chronic lower back pain. The trial met a critical milestone after an independent safety review confirmed CELZ-201's favorable safety profile. With enrollment complete, CELZ is now progressing to data analysis and后期 follow-up. CELZ-201, an "off-the-shelf" allogenic cell therapy, ...
2025-12-17 14:15
Creative Medical Technology Holdings Says WHO Assigns "Olastrocel" As International Non-Proprietary Name For Lead Cell Therapy CELZ-201
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company developing next-generation regenerative and immune cell therapies, today announced
2025-12-02 22:19
Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201
Creative Medical Technology Holdings, Inc. announced that the World Health Organization (WHO) has approved "olastrocel" as the International Non-Proprietary Name (INN) for CELZ-201, the company's lead allogeneic cell therapy. This milestone provides a globally standardized scientific identity, enhancing international clarity and regulatory positioning, and supports the advancement of olastrocel across large unmet-need markets. The therapy targets...
2025-12-02 14:15
Creative Medical Technology Approves Executive Bonuses
The latest update is out from Creative Medical Technology Holdings ( ($CELZ) )....
2025-11-12 19:47
快讯 | Creative Medical Technology Holdings 宣布达成认股权证行使协议，获得 420 万美元的总收益
Creative Medical Technology Holdings Announces Agreements for Exercise of Warra...
2025-10-29 21:00
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds
Creative Medical Technology Holdings, Inc. (CELZ) has entered into agreements with certain warrant holders to exercise outstanding warrants for up to 1,116,136 shares at $3.75 per share, generating approximately $4.2 million in gross proceeds. The company will issue new warrants for up to 2,790,340 shares, exercisable at $3.75 per share, subject to potential price reduction. The transaction is expected to close on October 29, 2025, with proceeds ...
2025-10-29 13:00
